Literature DB >> 33631465

Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors.

Boshi Huang1, Rama Gunta1, Huiqun Wang1, Mengchu Li1, Danni Cao2, Rolando E Mendez3, James C Gillespie3, Chongguang Chen4, Lan-Hsuan M Huang4, Lee-Yuan Liu-Chen4, Dana E Selley3, Yan Zhang5.   

Abstract

In the present study, the role of 3-hydroxy group of a series of epoxymorphinan derivatives in their binding affinity and selectivity profiles toward the opioid receptors (ORs) has been investigated. It was found that the 3-hydroxy group was crucial for the binding affinity of these derivatives for all three ORs due to the fact that all the analogues 1a-e exhibited significantly higher binding affinities compared to their counterpart 3-dehydroxy ones 6a-e. Meanwhile most compounds carrying the 3-hydroxy group possessed similar selectivity profiles for the kappa opioid receptor over the mu opioid receptor as their corresponding 3-dehydroxy derivatives. [35S]-GTPγS functional assay results indicated that the 3-hydroxy group of these epoxymorphinan derivatives was important for maintaining their potency on the ORs with various effects. Further molecular modeling studies helped comprehend the remarkably different binding affinity and functional profiles between compound 1c (NCP) and its 3-dehydroxy analogue 6c.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3-Hydroxy group; Binding affinity; Molecular docking; Opioid receptors; Selectivity

Mesh:

Substances:

Year:  2021        PMID: 33631465      PMCID: PMC8009840          DOI: 10.1016/j.bioorg.2021.104702

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  49 in total

1.  TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys.

Authors:  T Endoh; A Tajima; N Izumimoto; T Suzuki; A Saitoh; T Suzuki; M Narita; J Kamei; L F Tseng; H Mizoguchi; H Nagase
Journal:  Jpn J Pharmacol       Date:  2001-03

2.  Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol.

Authors:  Ao Zhang; Fuying Li; Chunyong Ding; Qizhen Yao; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2007-05-09       Impact factor: 7.446

3.  14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Authors:  Guo Li; Lindsey C K Aschenbach; Hengjun He; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-12-29       Impact factor: 2.823

4.  Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Authors:  Yunyun Yuan; Saheem A Zaidi; Orgil Elbegdorj; Lindsey C K Aschenbach; Guo Li; David L Stevens; Krista L Scoggins; William L Dewey; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2013-11-07       Impact factor: 7.446

5.  Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan.

Authors:  H Nagase; J Hayakawa; K Kawamura; K Kawai; Y Takezawa; H Matsuura; C Tajima; T Endo
Journal:  Chem Pharm Bull (Tokyo)       Date:  1998-02       Impact factor: 1.645

6.  Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators.

Authors:  Huiqun Wang; Bethany A Reinecke; Yan Zhang
Journal:  J Comput Aided Mol Des       Date:  2020-03-19       Impact factor: 3.686

7.  Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor.

Authors:  Tao Che; Susruta Majumdar; Saheem A Zaidi; Pauline Ondachi; John D McCorvy; Sheng Wang; Philip D Mosier; Rajendra Uprety; Eyal Vardy; Brian E Krumm; Gye Won Han; Ming-Yue Lee; Els Pardon; Jan Steyaert; Xi-Ping Huang; Ryan T Strachan; Alexandra R Tribo; Gavril W Pasternak; F Ivy Carroll; Raymond C Stevens; Vadim Cherezov; Vsevolod Katritch; Daniel Wacker; Bryan L Roth
Journal:  Cell       Date:  2018-01-04       Impact factor: 41.582

8.  Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Authors:  Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; Jesper M Mathiesen; Roger K Sunahara; Leonardo Pardo; William I Weis; Brian K Kobilka; Sébastien Granier
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

9.  Repeated Administration of Norbinaltorphimine Produces Cumulative Kappa Opioid Receptor Inactivation.

Authors:  Charles Chavkin; Joshua H Cohen; Benjamin B Land
Journal:  Front Pharmacol       Date:  2019-02-06       Impact factor: 5.810

Review 10.  Untangling the complexity of opioid receptor function.

Authors:  Rita J Valentino; Nora D Volkow
Journal:  Neuropsychopharmacology       Date:  2018-09-24       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.